Ascendis Pharma A/S Declines Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Ascendis Pharma A/S experienced a decline of 5.04%, crossing below its 5-day SMA, reflecting broader market trends.
The Nasdaq-100 saw a slight increase of 0.18%, while the S&P 500 dipped by 0.04%, indicating mixed market sentiment that may have influenced biotech stocks negatively.
Investors are cautious as the biotech sector continues to face challenges, leading to a negative outlook for stocks like Ascendis Pharma A/S.
Analyst Views on ASND
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 267.50 USD with a low forecast of 240.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
Current: 223.950
Low
240.00
Averages
267.50
High
325.00
About ASND
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
